fbpx

Molecular Profiling: Personalizing Treatment for Breast Cancer

Share Button

“The genetics of a tumor make each patient’s cancer unique. For example, doctors now know that there are many different types of breast cancer with distinct molecular patterns, or profiles.”

If your doctor tells you that “you have breast cancer (BC)” you are bound to be terrified. But you shouldn’t be. At least not yet. BC varies by age (the person’s age), stage and “molecular profile.” No two BC diagnoses are the same. You MUST ask your onc the right questions, get ALL the information to make the best decisions for you.

Have you been diagnosed with BC? Do you know your stage? Symptoms?

I am both a cancer survivor and cancer coach. I work with cancer patients to understand therapies, both conventional and non-conventional, that will help them achieve their goals. I also work with patients to determine what those goals are…

Please scroll down the page, post a question or comment and I will reply to you ASAP.

Thanks,

David Emerson

  • Cancer Survivor
  • Cancer Coach
  • Director PeopleBeatingCancer

Recommended Reading:


Molecular Profiling: Personalizing Treatment for BC

“The genetics of a tumor make each patient’s cancer unique. For example, doctors now know that there are many different types of breast cancer with distinct molecular patterns, or profiles. These distinct genetic changes can cause the breast cancer to be more or less likely to respond to certain therapies…

In recent years, researchers have made increasing use of an approach called molecular profiling to better understand the genetic makeup of breast tumors…

What is molecular profiling?

Because no two cancers are alike, cancer treatment plans shouldn’t be either. Molecular profiling characterizes the genetic and molecular structure of a tumor by identifying targets known as tumor biomarkers, which are biological molecules found in the blood, other body fluids or tissues. Based on the information gathered from a patient’s tumor, doctors are able to identify the appropriate therapies that target the biomarkers within an individual patient’s cancer cells…

BC Molecular Subtypes Respond Differently to Preoperative Chemotherapy

“BC is a clinically heterogeneous disease. Histologi- cally similar tumors may have different prognoses and may respond to therapy differently. It is believed that these differences in clinical behavior are due to molecular differences betweenhistologicallysimilartumors.DNAmicroarraytech- nology is ideally suited to reveal such molecular differences…

In summary, these results indicate that the major molecular classes of breast cancer can be detected in gene expression data regardless of tissue sampling method (i.e., fine needle aspirations, core needle, or surgical biopsies). The different molecular classes of breast cancer not only have different prognoses but also show distinct sensitivities to preoperative chemotherapy. The basal-like and erbB2+ subtypes of breast cancer are more sensitive to paclitaxel- and doxorubicin- containing preoperative chemotherapy than the luminal and normal-like cancers. The genes associated with pathologic CR were different between the basal-like and erbB2+ subgroups, which suggest that the mechanisms of chemotherapy sensi- tivity may vary across the subtypes. The possibility that distinct predictive signatures can be developed for the different molecular subtypes of breast cancer warrants further examination.”

 

Leave a Comment: